BI 3000202

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameBI 3000202
Drug Alias NameBI 3000202BI-3000202
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsType I InterferonopathiesLupus Erythematosus, SystemicHepatic Insufficiency
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaUnited States +[27] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co KgBoehringer Ingelheim International Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsType I InterferonopathiesLupus Erythematosus, SystemicHepatic Insufficiency
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A